Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laroprovstat/Rosuvastatin vs Rosuvastatin in Hypercholesterolaemia
NCT07619118Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Primary completion
- May 2027
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of laroprovstat in hypercholesterolemia (8 arms), sponsored by AstraZeneca. Primary endpoint: Low-Density Lipoprotein Cholesterol at 8 weeks. Started Sep 2026; status: recruiting.
02
Drugs
laroprovstat
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07619118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619118.